Kyowa Hakko to Begin Clinical Phase II Trials in the U. S. and Europe of KW-7158, a Treatment for Urinary Incontinence
Kyowa Hakko Kogyo Co. this month started clinical phase II trials of KW-7158, a treatment for urinary incontinence, following positive results from the clinical pharmacological study carried out in France from June last year.
(PRWEB) May 16, 2002
Tokyo, Japan, May 2002 - (JCN Newswire) - Kyowa Hakko Kogyo Co. this month started clinical phase II trials of KW-7158, a treatment for urinary incontinence, following positive results from the clinical pharmacological study carried out in France from June last year. These results support very encouraging preclinical data obtained in animal studies.
Originally developed by Kyowa Hakko, KW-7158 is intended to prevent the sense of urgency, urinary frequency and incontinence caused by overactive bladder contractions by uniquely acting on the peripheral sensory nerves to control bladder activities.
KW-7158 is expected to have reduced side effects compared with anticholinergic drugs, which are currently used to treat urinary incontinence. Anticholinergic drugs have well known side effects such as dry mouth, urinary retention, blurred vision and more. Kyowa Hakko considers KW-7158 to be a promising new treatment and is actively pursuing its development.
"We are very excited about the development of KW-7158. It's a compound with a totally new mechanism and the results we have obtained from the clinical pharmacological tests have been very positive," said Hiroyuki Kuniyasu, executive officer of pharmaceuticals research & development at the Pharmaceuticals business of Kyowa Hakko.
In recent years, as the proportion of elderly people has grown in countries around the world, the number of incontinence sufferers has grown rapidly. There are said to be more than 2.4 million sufferers in Japan and a total 20 million sufferers in Japan, the US and Europe.
About Kyowa Hakko Kogyo Co. Ltd.
Kyowa Hakko (TSE: 4151), a leading Japanese research-based pharmaceutical and biotechnology company, is devoted to discovering, developing, manufacturing, and marketing quality pharmaceutical products and bio-chemicals such as amino acids. Six compounds including KW-6002(an agent for the treatment of Parkinson's disease) and KW-7158 as strategic themes are now under development overseas. Additionally, its pharmaceutical central research is focused on two therapeutic fields and drug discovery utilizing antibody-based technologies. Those therapeutic fields include cancer and allergies, where Kyowa Hakko has a strong background worldwide with products such as Mitomycin and Olopatadine. technology, and a commitment to research, Kyowa Hakko's products are known for high-quality, reliability and cost-effectiveness. For further information, please visit the Kyowa Hakko Kogyo Co. Ltd. home page at: www. kyowa. co. jp
Contact:
Ichiro Matsuura
Manager, Corporate Communications Department
KYOWA HAKKO KOGYO CO., LTD.
1-6-1 Ohtemachi, Chiyoda-ku
Tokyo 100-8185 JAPAN
TEL +81-3-3282-1903
FAX +81-3-3282-0990
E-mail pr@kyowa. co. jp
May. 14, 2002, 16:18 (JST)
From the Japan Corporate News Network
Http://www. japancorp. net (http://www. japancorp. net)
Topic: New Product
Sectors: Clinical Trials, Health & Pharm General
2002 Japan Corporate News Network
